In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates
Microorganisms · 25.08.2023 · 11 (9) · 2158
DOI: 10.3390/microorganisms11092158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microorganisms, online erschienen am 25.08.2023. Verfasst von Tze-Peng Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Singapore General Hospital, 10 Hospital Boulevard, Singapore 168582, Singapore. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Medical Research Council, Pfizer Inc, NY, USA, National Medical Research Council, Singapore.
Abstract (Originalsprache)
The emergence of carbapenem-resistant Enterobacterales (CRE) has been recognized as a significant concern globally. Ceftazidime/avibactam (CZA) is a novel β-lactam/β-lactamase inhibitor that has demonstrated activity against isolates producing class A, C, and D β-lactamases. Here-in, we evaluated the in vitro activity of CZA and comparator antimicrobial agents against 858 CRE isolates, arising from the Southeast Asian region, collected from a large tertiary hospital in Singapore. These CRE isolates mainly comprised Klebsiella pneumoniae (50.5%), Escherichia coli (29.4%), and Enterobacter cloacae complex (17.1%). Susceptibility rates to levofloxacin, imipenem, meropenem, doripenem, aztreonam, piperacillin/tazobactam, cefepime, tigecycline, and polymyxin B were low. CZA was the most active β-lactam agent against 68.9% of the studied isolates, while amikacin was the most active agent among all comparator antibiotics (80% susceptibility). More than half of the studied isolates (51.4%) identified were Klebsiella pneumoniae carbapenemase (KPC)-2 producers, 25.9% were New Delhi metallo-β-lactamase (NDM) producers, and Oxacillinase (OXA)-48-like producers made up 10.7%. CZA was the most active β-lactam agent against KPC-2, OXA-48-like, and Imipenemase (IMI) producers (99.3% susceptible; MIC50/90: ≤1/2 mg/L). CZA had excellent activity against the non-carbapenemase-producing CRE (91.4% susceptible; MIC50/90: ≤1/8 mg/L). Expectedly, CZA had no activity against the metallo-β-lactamases (MBL)-producing CRE (NDM- and Imipenemase MBL (IMP) producers; 27.2% isolates), and the carbapenemase co-producing CRE (NDM + KPC, NDM + OXA-48-like, NDM + IMP; 3.0% isolates). CZA is a promising addition to our limited armamentarium against CRE infections, given the reasonably high susceptibility rates against these CRE isolates. Careful stewardship and rational dosing regimens are required to preserve CZA’s utility against CRE infections.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Singapore General Hospital, 10 Hospital Boulevard, Singapore 168582, Singapore.
- SingHealth Duke-NUS Pathology Academic Clinical Programme, 20 College Road, Singapore 169856, Singapore.
- SingHealth Duke-NUS Medicine Academic Clinical Programme, 10 Hospital Boulevard, Singapore 168582, Singapore.
- Department of Microbiology, Singapore General Hospital, 20 College Road, Singapore 169856, Singapore.
- Department of Infectious Diseases, Singapore General Hospital, 20 College Road, Singapore 169856, Singapore.
- Emerging Infectious Diseases Program, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
ORCID-Profile: Tze-Peng Lim
Förderung
- National Medical Research Council
- Pfizer Inc, NY, USA
- National Medical Research Council, Singapore
- Pfizer Inc., New York, NY, USA
Zitieren
APA
Lim, T. P., Ho, J. Y., Teo, J. Q., Sim, J. H., Tan, S. H., Tan, T. T., & Kwa, A. L. (2023). In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates. Microorganisms, 11(9), 2158. https://doi.org/10.3390/microorganisms11092158
Vancouver
Lim TP, Ho JY, Teo JQ, Sim JH, Tan SH, Tan TT, et al. In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates. Microorganisms. 2023;11(9):2158. doi:10.3390/microorganisms11092158
BibTeX
@article{Lim2023,
author = {Lim, Tze-Peng and Ho, Jun-Yuan and Teo, Jocelyn Qi-Min and Sim, James Heng-Chiak and Tan, Si-Hui and Tan, Thuan-Tong and Kwa, Andrea Lay-Hoon},
title = {In Vitro Susceptibility to Ceftazidime-Avibactam and Comparator Antimicrobial Agents of Carbapenem-Resistant Enterobacterales Isolates},
journal = {Microorganisms},
year = {2023},
volume = {11},
number = {9},
pages = {2158},
doi = {10.3390/microorganisms11092158}
}
EUVIMED